Implantable Continuous Glucose Monitors (I-CGM)

Medicare covers FDA-approved therapeutic implantable continuous glucose monitors for beneficiaries with diabetes mellitus when prescribed per FDA indications and when the treating practitioner documents sufficient beneficiary (or caregiver) training and a provider order. Coverage requires that the beneficiary is insulin-treated or has documented problematic hypoglycemia (recurrent level 2 events or one level 3 event), with ongoing adherence documented by an in-person or Medicare-approved telehealth visit every six months; devices are not covered for short-term (72 hours to 1 week) diagnostic use.

"Beneficiary has diabetes mellitus (use applicable ICD-10 diagnosis codes per the LCD-related Policy Article)."

Sign up to see full coverage criteria, indications, and limitations.